HJ Science Co., Ltd. (Ticker: 6132 HK) is a Chinese biotechnology company developing new medicines for immune system disorders, metabolic conditions and cancer. Founded in 2017, the company is still in the clinical-stage, meaning its main drug candidates are being tested and have not yet reached broad commercial launch.

HJ Science’s three main drug candidates target conditions including skin inflammation diseases such as atopic dermatitis and psoriasis, type 2 diabetes and potential weight-management uses, and a form of lung cancer linked to a specific genetic mutation.

HJ Science plans to list H shares on the Hong Kong Stock Exchange Main Board on June 23, 2026. According to published terms, the company priced its IPO at HKD 81.80 per share, offering 13.60 million primary shares and raising approximately HKD 1.11 billion, or about USD 142 million. The IPO implies a market capitalization at offer of approximately USD 768 million.

According to the prospectus summary, IPO proceeds will be used for R&D and product capacity, brand promotion and business development, working capital and strategic acquisitions.